A PK study to compare JPB898 (proposed nivolumab biosimilar) and US-licensed Opdivo® in participants with resected stage IIB, IIC, or III melanoma in the adjuvant setting

What you commit to

• Study type: Interventional · Phase 1
• Planned participants: 83
• 34 sites in 4 countries
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.

AI-kivonat: who the study is looking for

Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults whose stage IIB, IIC or III melanoma has been surgically removed and who need adjuvant treatment (treatment after surgery). It compares JPB898 with Opdivo.

Age

18 years or older

Sex

All sexes can join

Disease stage

Melanoma stage IIB, IIC or III, removed by surgery, needing adjuvant treatment

Read by machine on 9 Nov 2026.

Sites (34)

Sites in registry order. Save your city in your profile to sort them by distance.

Are you the coordinator? Confirm the details